Planning and Analyzing Clinical Trials with Composite Endpoints
Planning and Analyzing Clinical Trials with Composite Endpoints (Springer Series in Pharmaceutical Statistics) by Geraldine Rauch
English | 19 Jun. 2018 | ISBN: 3319737694 | 272 Pages | PDF | 2.29 MB
English | 19 Jun. 2018 | ISBN: 3319737694 | 272 Pages | PDF | 2.29 MB
This book addresses the most important aspects of how to plan and evaluate clinical trials with a composite primary endpoint to guarantee a clinically meaningful and valid interpretation of the results. Composite endpoints are often used as primary efficacy variables for clinical trials, particularly in the fields of oncology and cardiology. These endpoints combine several variables of interest within a single composite measure, and as a result, all variables that are of major clinical relevance can be considered in the primary analysis without the need to adjust for multiplicity. Moreover, composite endpoints are intended to increase the size of the expected effects thus making clinical trials more powerful.